|

Serplulimab Clinical Trials

28 actively recruiting trials

▲ +3 trials since May 2026

Also known as: Carboplatin, Cisplatin, Concurrent radiotherapy Maintenance therapy, Etoposide, HLX-10LX +7 more

Pipeline

Phase 1: 1Phase 2: 23Phase 1/2: 1Phase 2/3: 1

Top Sponsors

  • Fudan University5
  • Sun Yat-sen University3
  • Tianjin Medical University Cancer Institute and Hospital2
  • Tang-Du Hospital2
  • Shanghai Henlius Biotech2

Indications

Other28 trials

A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy
Phase 2
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
Phase 2
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
Phase 1/2
A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
Phase 2
Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
Phase 2
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
Phase 2
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
N/A
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
Phase 2
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
Phase 2
NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
Phase 2
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Phase 2/3
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
Phase 2
Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer
Phase 2
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
Phase 2
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Phase 2
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Phase 2
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
Phase 2
Serplulimab Combined With CCRT for LS-SCLC.
Phase 2
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Phase 2
Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
Phase 2
Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%
Phase 2
Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors
Phase 2
Serplulimab for Locally Advanced Cervical Cancer
Phase 2
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
Phase 1
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
Phase 2
The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.